Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
Sumitomo Pharma and its global partner Otsuka Pharmaceutical said on July 31 that their hoped-to-be blockbuster ulotaront failed to hit the primary endpoints in two PIII studies conducted in the US for acutely psychotic adults with schizophrenia. The topline data…
To read the full story
Related Article
BUSINESS
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Santen’s Myopia Drug Ryjusea Wins Nod in Philippines
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…